Abstract:Abstract Background Metabolomics is increasingly recognized for uncovering pathophysiology and identifying diagnostic and prognostic biomarkers in inflammatory bowel disease (IBD). This study focuses on exploring comprehensive serum metabolomic profiles and corresponding specific metabolic pathways, in order to differentiate IBD patients from healthy individuals and to accurately identify IBD subtypes (Crohn's disease [CD], ulcerative colitis [UC]) through serum biomarkers with high patient acceptability. Methods Serum samples with matched clinical metadata were comprehensively collected from patients with IBD at Kyung Hee University Hospital, Seoul, Korea. Corresponding samples from normal controls (NCs) were obtained for comparison. Untargeted profiling was performed with Gas Chromatography-Time-Of-Flight-Mass Spectrometry, and targeted profiling of bile acids and tryptophan used Liquid Chromatography-Triple Quadrupole-Mass Spectrometry. The identification of distinct metabolites and potential biomarkers was achieved through extensive univariate and multivariate statistical analyses. Receiver operating characteristic (ROC) curves and metabolic pathway analyses were also conducted. Results A total of 346 subjects were analyzed, comprising 258 IBD patients (134 with CD and 124 with UC) and 88 NCs, Table 1. The patients with IBD were clearly clustered from the NCs, while IBD subgroups were not clearly separated from each other in the nontargeted profiling. Tryptophan and indole-3-acetic acid were elevated in both patients with CD and UC, while kynurenine and indole-3-propionic acid increased only in CD. Conversely, patients with UC had lower levels of indole-3-acetic acid, serotonin, and acetylcholine compared to CD. The ratio of primary and secondary bile acids was also significantly decreased in both patient groups compare with NCs. The ROC curves (Figure 1A) showed good discriminatory power for NCs vs CD (AUC:0.9738), NCs vs UC (AUC:0.9887), and UC vs CD (AUC:0.7140). Pathway analysis of the identified metabolites showed a sustained change in glyoxylate and dicarboxylate metabolism/alanine, aspartate and glutamate metabolism/glycine, serine and threonine metabolism associated with all comparisons (NCs vs UC, NCs vs CD, UC vs CD). Beta-alanine, arginine, and proline metabolism were linked to IBD compared to NCs. Glycerolipid metabolism distinctly differed between UC and CD (Figure 1B-1D). Network analysis revealed associations between metabolomic markers and specific clinical phenotypes of IBD subtypes. Conclusion This study demonstrates that serum metabolomic biomarkers are novel and effective tools for diagnosing IBD, as well as for identifying and characterizing its subtypes and associated phenotypes.

What problem does this paper attempt to address?

This paper attempts to solve the problems of diagnosis and classification of inflammatory bowel disease (IBD) through serum metabolomic markers. Specifically, the study aims to explore comprehensive serum metabolomic features and their specific metabolic pathways to distinguish IBD patients from healthy individuals, and accurately identify different subtypes of IBD (Crohn's disease [CD] and ulcerative colitis [UC]) through serum biomarkers, while improving patient acceptance. ### Main Objectives: 1. **Distinguish IBD patients from healthy individuals**: By analyzing the differences in metabolites in serum samples, determine the biomarkers that can effectively distinguish IBD patients from healthy control groups. 2. **Identify and distinguish IBD subtypes**: Further through metabolomic analysis, identify specific biomarkers that can distinguish Crohn's disease (CD) and ulcerative colitis (UC). 3. **Explore changes in metabolic pathways**: Through metabolic pathway analysis, understand which metabolic pathways have significantly changed in IBD patients, thereby providing new insights into the pathophysiological mechanisms of the disease. ### Methods: - **Sample collection**: Serum samples of IBD patients were collected from Kyung Hee University Hospital in South Korea, and samples of healthy control groups were matched. - **Metabolomic analysis**: Non - targeted metabolomic analysis was carried out using gas chromatography - time - of - flight mass spectrometry (GC - TOF - MS), and targeted metabolomic analysis of bile acids and tryptophan was carried out using liquid chromatography - triple quadrupole mass spectrometry (LC - MS/MS). - **Statistical analysis**: Specific metabolites and potential biomarkers were identified through univariate and multivariate statistical analyses, and the diagnostic efficacy of these markers was evaluated using the receiver operating characteristic curve (ROC curve). - **Metabolic pathway analysis**: Metabolic pathway analysis was carried out on the identified metabolites to reveal their change patterns in different comparisons. ### Results: - **Distinction between patients and healthy control groups**: There are obvious metabolite differences between IBD patients and healthy control groups, and the ROC curve shows good discrimination ability (NCs vs CD: AUC = 0.9738; NCs vs UC: AUC = 0.9887). - **Distinction of IBD subtypes**: Although non - targeted analysis failed to clearly distinguish CD and UC subtypes, targeted analysis found some specific metabolite differences. For example, tryptophan and indole - 3 - acetic acid were elevated in both CD and UC, while the serotonin and acetylcholine levels in UC patients were lower. - **Changes in metabolic pathways**: Pathways such as glucuronic acid and dicarboxylic acid metabolism, alanine, aspartic acid and glutamic acid metabolism, glycine, serine and threonine metabolism showed continuous changes in all comparisons. β - alanine, arginine and proline metabolism also changed significantly in IBD patients, and glycerophospholipid metabolism was significantly different between UC and CD. ### Conclusions: This study proves that serum metabolomic markers are effective tools for diagnosing IBD and its subtypes, and can be used to identify and characterize different subtypes of IBD and their related phenotypes. This provides new ideas and methods for the clinical diagnosis and treatment of IBD.

P140 Serum Metabolomic Biomarkers Can Identify and Characterize Associated Subtypes and Phenotypes in Inflammatory Bowel Disease

Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease.

Serum proteome profiles to differentiate Crohn disease from intestinal tuberculosis and primary intestinal lymphoma: A pilot study.

Alterations in lipid, amino acid, and energy metabolism distinguish Crohn’s disease from ulcerative colitis and control subjects by serum metabolomic profiling

P1230 Integrated analysis of microbiome and metabolome reveals disease-specific profiles in inflammatory bowel disease and intestinal Behcet’s disease

P324 Urine metabolite profile characterizes clinical activity and disease extent in patients with inflammatory bowel disease

Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease

Identification of candidate biomarkers for inflammatory bowel disease using non-targeted serum metabolomics

Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behçet's Disease

P018 Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery

IDDF2019-ABS-0186 Correlation Between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

P106 Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach

Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets

DOP33 Distinct perturbances in metabolic pathways associate with disease progression in patients with Inflammatory Bowel Disease

Lipidomic Profiling in Inflammatory Bowel Disease: Comparison Between Ulcerative Colitis and Crohn's Disease.

P180 Novel biomarkers associated with inflammatory bowel disease

Lipidomic Profiling in Inflammatory Bowel Disease

P380 Integrated fecal metagenome and serum metabolome analysis revealed gut microbiome associated serum metabolites as diagnostic biomarkers for inflammatory bowel disease

DOP26 Metagenomic and metabolomic profiles in IBD: understanding microbial and metabolic shifts from a large deeply phenotyped cohort

From serum metabolites to the gut: revealing metabolic clues to susceptibility to subtypes of Crohn's disease and ulcerative colitis

Inferring intestinal mucosal immune cell associated microbiome species and microbiota-derived metabolites in inflammatory bowel disease